Skip to main content
. 2019 Dec 20;59(9):2325–2333. doi: 10.1093/rheumatology/kez602

Fig. 1.

Fig. 1

Patient disposition during the 3-year post-trial follow-up

AE: adverse event; EOS: end of study; Follow-up: post-trial follow-up; Lost: lost to follow-up; MTX: methotrexate + placebo–tocilizumab initiation strategy group; TCZ: tocilizumab + placebo–MTX initiation strategy group; TCZ+MTX: tocilizumab + MTX initiation strategy group; UAE: U-Act-Early; Withdr. Consent: withdrawal of consent.